16.03.2016 | Original Article – Cancer Research | Ausgabe 6/2016

Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)
- Zeitschrift:
- Journal of Cancer Research and Clinical Oncology > Ausgabe 6/2016